Genezen reports that the company became the first CDMO to license CSL’s Cytegrity™ cell line production system that was designed for the production of lentiviral vectors (LVVs). “We have significant, ...
CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results